Search Results
Pirtobrutinib vs nemtabrutinib in CLL
BELLWAVE-001: nemtabrutinib in patients with R/R CLL/SLL
Updated analysis of BELLWAVE-001: nemtabrutinib in R/R CLL
Current state of the field: non-covalent BTK inhibitors for CLL
Ongoing trials investigating the efficacy of pirtobrutinib in CLL
The promise of pirtobrutinib in the treatment of CLL
BRUIN study update: analysis of the mechanisms of resistance to pirtobrutinib in CLL
An update from BELLWAVE-001: nemtabrutinib in CLL/SLL
Pirtobrutinib resistance in CLL: early findings
Genomic evolution and resistance to pirtobrutinib in CLL: insights from the BRUIN study
Nemtabrutinib (ARQ 531) in covalent BTKi resistant CLL
MAIC of pirtobrutinib vs venetoclax in patients with R/R CLL previously treated with a covalent BTKi
